Skip to main content

Xenon and Genentech Ink Rx, Companion Dx Collaboration and License Pact

NEW YORK (GenomeWeb News) – Canadian drug discovery firm Xenon said this week that it will collaborate with Genentech to discover and develop compounds and companion diagnostics for treating pain.

The pact could bring Burnaby, BC-based Xenon up to $646 million in total payments.

The agreement gives Genentech a non-exclusive license to develop and commercialize diagnostics developed under the collaboration and an exclusive license to compounds, Xenon said.

Xenon will receive an undisclosed upfront payment, research funding, and payments for research, development, and commercialization milestones, as well as royalties on sales of products resulting from the collaboration.

Xenon's discovery and development efforts focus on development of small-molecule therapies based on the genetic causes of metabolic, neurological, and cardiovascular diseases.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.